Beacon Trust Co. continued to hold its position in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, Holdings Channel reports. The fund owned 176,142 shares of the biopharmaceutical company’s stock at the end of the second quarter. Beacon Trust Co.’s holdings in Pfizer were worth $5,220,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Stelac Advisory Services LLC purchased a new stake in Pfizer during the second quarter worth approximately $110,000. Catamount Wealth Management raised its position in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares in the last quarter. Commonwealth Financial Services LLC raised its position in shares of Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 210 shares in the last quarter. Stuart Chaussee & Associates Inc. raised its position in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares in the last quarter. Finally, Jag Capital Management LLC bought a new position in shares of Pfizer during the second quarter valued at about $202,000. Hedge funds and other institutional investors own 69.65% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded up 0.30% during trading on Wednesday, hitting $33.93. 10,482,626 shares of the stock were exchanged. The firm has a market capitalization of $205.81 billion, a price-to-earnings ratio of 30.08 and a beta of 0.87. The company has a 50-day moving average price of $34.60 and a 200 day moving average price of $34.02. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. The company had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. Pfizer’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.56 EPS. Equities analysts predict that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a yield of 3.55%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is 95.24%.
Several research analysts recently issued reports on the stock. Argus reissued a “buy” rating and set a $39.00 target price on shares of Pfizer in a research note on Sunday, August 28th. Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a research note on Monday. Jefferies Group reissued a “buy” rating and set a $42.00 target price (up from $41.00) on shares of Pfizer in a research note on Tuesday, June 14th. Vetr lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 target price on the stock. in a research note on Tuesday, June 28th. Finally, Citigroup Inc. reissued a “neutral” rating and set a $37.00 target price on shares of Pfizer in a research note on Wednesday, August 3rd. Ten research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.